AN2 Therapeutics, Inc. (ANTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 34.45M |
| Enterprise Value | 14.5M |
| P/E Ratio | -4.91 |
| PEG Ratio | -0.16 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 2.25 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -2.64 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0.39 |
| Return On Equity | -0.52 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -35.17M |
| Net Income | -35.17M |
| Diluted EPS | -1.16 |
| Total Cash | 85.29M |
| Total Cash/Share | 2.5 |
| Total Debt | 0 |
| Total Debt/Equity | 0 |
| Current Ratio | 15.73 |
| Book Value Per Share | 2.4 |
| 52-Week Change | 404.67 |
| 52-Week High | 6.91 |
| 52-Week Low | 1 |
| Moving Average 50 Days | 4.33 |
| Moving Average 200 Days | 2.3 |
| Average Volume | 290,756 |
| Shares Outstanding | 27.4M |
| % Held by Institutions | 72.46 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |